Charles River Laboratories International, Inc.
CRL · NYSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -9.41 | -8.14 | 0.98 | 8.48 |
| FCF Yield | 5.29% | 3.02% | 2.66% | 2.81% |
| EV / EBITDA | 20.67 | 14.44 | 14.13 | 26.37 |
| Quality | ||||
| ROIC | 0.95% | 7.14% | 7.84% | 8.12% |
| Gross Margin | 32.88% | 36.39% | 36.79% | 37.70% |
| Cash Conversion Ratio | 29.04 | 1.42 | 1.26 | 1.91 |
| Growth | ||||
| Revenue 3-Year CAGR | 0.62% | 5.27% | 10.79% | 10.54% |
| Free Cash Flow Growth | 37.29% | 23.89% | -44.57% | 40.00% |
| Safety | ||||
| Net Debt / EBITDA | 4.35 | 2.70 | 2.90 | 3.27 |
| Interest Coverage | 1.80 | 4.52 | 10.98 | 7.98 |
| Efficiency | ||||
| Inventory Turnover | 9.76 | 6.91 | 9.83 | 11.07 |
| Cash Conversion Cycle | 83.53 | 98.34 | 76.31 | 66.45 |